期刊文献+

59例乳腺癌的临床与病理分析 被引量:2

Clinical and pathological analysis in 59 cases of breast cancer
下载PDF
导出
摘要 目的研究59例乳腺癌的临床特征、病理与乳腺癌中ER、PR、p53、CerbB-2等的表达情况。方法对59例患者的临床资料、病理类型及免疫组化结果进行回顾性分析。结果乳腺癌中ER、PR、p53、CerbB-2表达阳性率为27.1%、54.2%、47.5%、55.9%。p53表达阳性与乳腺癌组织学分级差异有统计学意义(P<0.05),与淋巴结转移差异有统计学意义(P<0.01)。结论乳腺癌中,p53表达与CerbB-2表达相关,p53表达阳性不仅与细胞癌变有关,而且与癌细胞的浸润和转移有关。 Objective To research the clinical and pathological results in 59 eases of breast cancer, especially the expression of ER,PR,p53,CerbB-2. Methods A retrospective analysis was made on 59 eases of breast cancer from Jan. 2004 to Oct. 2005. All of them were treated in our hospital. Results The positive rates of ER, PR, p53, CerbB-2 in breast cancer were 27. 1%, 54. 2 %, 47. 5 %, 55.9 % respectively. A statistically significant relation was found between the presence of p53 and lymph node metastasis(P 〈0.01),the presence of p53 was also associated with the histological typing in breast cancer. (P〈0. 05). Conclusion There is a correlation between the expression of p53 and CerbB-2. p53 is assoicated with carcinogenesis development and local invasion in breast cancer.
出处 《重庆医学》 CAS CSCD 2006年第23期2144-2145,共2页 Chongqing medicine
关键词 乳腺癌 P53 CERBB-2 breast cancer p53 CerbB-2
  • 相关文献

参考文献5

二级参考文献23

  • 1陈艺华,董敬朋,李春德,陆药丹,张盛.人乳腺癌c-erbB2基因扩增及过度表达的研究[J].中华肿瘤杂志,1995,17(1):16-19. 被引量:23
  • 2石美鑫 熊汝成 等.实用外科学[M].北京:人民卫生出版社,1994.587.
  • 3[1]Isobe M, Emanuel BS, Givol D, et al. Localization of gene for human p53 tumor antigene to band 17p13.Nature,1986;320:84
  • 4[2]Culotta E, Koshland JDE. P53 sweeps through cancer research. Science, 1993; 262; 1958
  • 5[3]Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor orf transformation.Cell,1989;57:1083
  • 6[4]Chen PL, Chen Y, Bookstein R, et al. Genetic mechanisms of tumor suppression by the human p53 gene. Science,1990;250:1576
  • 7[5]Bae Ⅰ, Fan S, Bhatia K, et al. Relationships between G1 arrest and stability of the p53 and P21Cipl/wafl proteins following γ- irradiation of human lymphoma cells. Cancer Res,1995;55:2387
  • 8[6]Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature,1991;352:345
  • 9[7]Lane DP. P53, guardian of the genome. Nature, 1992;358:15
  • 10[8]Greenblatt MS, Bennett WP, Hollstein M, et al.Mutations in the p53 tumor suppressor gene:clues to cancer etiology and molecular pathogenesis. Cancer Res,1994;54:4855

共引文献14

同被引文献21

  • 1林淑端,陈丽珍,朱映晖.乳腺癌细针穿刺活检的体会[J].国际医药卫生导报,2005,11(12):68-70. 被引量:5
  • 2蔡清清,黄慧强,林天歆,姜文奇.乳腺癌患者外周血中循环癌细胞的检测及其临床意义[J].癌症,2005,24(7):837-841. 被引量:18
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 4Pantel K, Brakenhoff R H, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour ceils[ J]. Nat Rev Cancer, 2008, 8(5): 329-340.
  • 5Hayes D F, Smerage J. Is there a role for circulating tumor cells in the management of breast cancer? [J]. Clin Cancer Res, 2008, 14(12) : 3646 - 3650.
  • 6Harvey J M, Clark G M, Osborne C K, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[ J]. J Clin Oncol, 1999, 17(5): 1474-1481.
  • 7Fehm T, Solomayer E F, Meng S, et al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells [J]. Cytotherapy, 2005, 7(2) :171-185.
  • 8Husemann Y, Geigl J B, Schubert F, et al. Systemic spread is an early step in breast cancer[ J]. Cancer Cell, 2008, 13 (1) : 58 -68.
  • 9Reuben J M, Krishnamurthy S, Woodward W, et al. The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy respons[J]. Expert Opin Med Diagn, 2008, 2(4) : 339 -348.
  • 10Smith B L. Approaches to breast-cancer staging [ J ]. N Engl J Med, 2000, 342(8) : 580-581.

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部